1287 related articles for article (PubMed ID: 30315511)
1. Urinary and Plasma Metabolomics Identify the Distinct Metabolic Profile of Disease State in Chronic Mouse Model of Multiple Sclerosis.
Singh J; Cerghet M; Poisson LM; Datta I; Labuzek K; Suhail H; Rattan R; Giri S
J Neuroimmune Pharmacol; 2019 Jun; 14(2):241-250. PubMed ID: 30315511
[TBL] [Abstract][Full Text] [Related]
2. Profile of Circulatory Metabolites in a Relapsing-remitting Animal Model of Multiple Sclerosis using Global Metabolomics.
Mangalam A; Poisson L; Nemutlu E; Datta I; Denic A; Dzeja P; Rodriguez M; Rattan R; Giri S
J Clin Cell Immunol; 2013 Jun; 4():. PubMed ID: 24273690
[TBL] [Abstract][Full Text] [Related]
3. Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis.
Poisson LM; Suhail H; Singh J; Datta I; Denic A; Labuzek K; Hoda MN; Shankar A; Kumar A; Cerghet M; Elias S; Mohney RP; Rodriguez M; Rattan R; Mangalam AK; Giri S
J Biol Chem; 2015 Dec; 290(52):30697-712. PubMed ID: 26546682
[TBL] [Abstract][Full Text] [Related]
4. Identification of Altered Metabolic Pathways during Disease Progression in EAE Mice via Metabolomics and Lipidomics.
Lee G; Hasan M; Kwon OS; Jung BH
Neuroscience; 2019 Sep; 416():74-87. PubMed ID: 31376423
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics approach based on utra-performance liquid chromatography coupled to mass spectrometry with chemometrics methods for high-throughput analysis of metabolite biomarkers to explore the abnormal metabolic pathways associated with myocardial dysfunction.
Zhao LK; Zhao YB; Yu PC; Zhang PX
Biomed Chromatogr; 2020 Aug; 34(8):e4847. PubMed ID: 32285481
[TBL] [Abstract][Full Text] [Related]
6. Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.
Singh J; Deshpande M; Suhail H; Rattan R; Giri S
J Neuroimmune Pharmacol; 2016 Mar; 11(1):84-97. PubMed ID: 26277791
[TBL] [Abstract][Full Text] [Related]
7. Identification of key metabolites during cisplatin-induced acute kidney injury using an HPLC-TOF/MS-based non-targeted urine and kidney metabolomics approach in rats.
Qu X; Gao H; Sun J; Tao L; Zhang Y; Zhai J; Song Y; Hu T; Li Z
Toxicology; 2020 Feb; 431():152366. PubMed ID: 31926187
[TBL] [Abstract][Full Text] [Related]
8. Study of the metabolomics characteristics of patients with metabolic syndrome based on liquid chromatography quadrupole time-of-flight mass spectrometry.
Wu N; Wang W; Yi M; Cheng S; Wang D
Ann Endocrinol (Paris); 2018 Feb; 79(1):37-44. PubMed ID: 29246383
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease.
Luan H; Liu LF; Tang Z; Zhang M; Chua KK; Song JX; Mok VC; Li M; Cai Z
Sci Rep; 2015 Sep; 5():13888. PubMed ID: 26365159
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of amino acids and acylcarnitines combined with untargeted metabolomics using ultra-high performance liquid chromatography and quadrupole time-of-flight mass spectrometry.
Roy C; Tremblay PY; Bienvenu JF; Ayotte P
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():40-9. PubMed ID: 27240302
[TBL] [Abstract][Full Text] [Related]
11. Utility of an untargeted metabolomics approach using a 2D GC-GC-MS platform to distinguish relapsing and progressive multiple sclerosis.
Datta I; Zahoor I; Ata N; Rashid F; Cerghet M; Rattan R; Poisson LM; Giri S
bioRxiv; 2024 Feb; ():. PubMed ID: 38370675
[TBL] [Abstract][Full Text] [Related]
12. NMR-Based Metabolomics Separates the Distinct Stages of Disease in a Chronic Relapsing Model of Multiple Sclerosis.
Dickens AM; Larkin JR; Davis BG; Griffin JL; Claridge TD; Sibson NR; Anthony DC
J Neuroimmune Pharmacol; 2015 Sep; 10(3):435-44. PubMed ID: 26155956
[TBL] [Abstract][Full Text] [Related]
13. A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica.
Gebregiworgis T; Nielsen HH; Massilamany C; Gangaplara A; Reddy J; Illes Z; Powers R
J Proteome Res; 2016 Feb; 15(2):659-66. PubMed ID: 26759122
[TBL] [Abstract][Full Text] [Related]
14. Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis.
Poddighe S; Murgia F; Lorefice L; Liggi S; Cocco E; Marrosu MG; Atzori L
Int J Biochem Cell Biol; 2017 Dec; 93():148-155. PubMed ID: 28720279
[TBL] [Abstract][Full Text] [Related]
15. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
16. Investigation of altered urinary metabolomic profiles of invasive ductal carcinoma of breast using targeted and untargeted approaches.
More TH; Taware R; Taunk K; Chanukuppa V; Naik V; Mane A; Rapole S
Metabolomics; 2018 Aug; 14(8):107. PubMed ID: 30830381
[TBL] [Abstract][Full Text] [Related]
17. Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis.
Gaetani L; Boscaro F; Pieraccini G; Calabresi P; Romani L; Di Filippo M; Zelante T
Front Immunol; 2020; 11():157. PubMed ID: 32132996
[TBL] [Abstract][Full Text] [Related]
18. LC-MS-based urinary metabolite signatures in idiopathic Parkinson's disease.
Luan H; Liu LF; Meng N; Tang Z; Chua KK; Chen LL; Song JX; Mok VC; Xie LX; Li M; Cai Z
J Proteome Res; 2015 Jan; 14(1):467-78. PubMed ID: 25271123
[TBL] [Abstract][Full Text] [Related]
19. Metabolome-based signature of disease pathology in MS.
Andersen SL; Briggs FBS; Winnike JH; Natanzon Y; Maichle S; Knagge KJ; Newby LK; Gregory SG
Mult Scler Relat Disord; 2019 Jun; 31():12-21. PubMed ID: 30877925
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
